US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

36.59

-2.2400-5.77%

Post-market: 36.590.00000.00%16:58 EDT

Volume:2.00M

Turnover:74.79M

Market Cap:2.19B

PE:-19.99

High:39.22

Open:38.29

Low:35.60

Close:38.83

52wk High:40.62

52wk Low:13.30

Shares:59.80M

Float Shares:35.00M

Volume Ratio:0.75

T/O Rate:5.73%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8300

EPS(LYR):-1.8300

ROE:-26.95%

ROA:-18.65%

PB:4.76

PE(LYR):-19.99

Loading ...

Overview Company News Filings

Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress

Simply Wall St.

Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares

Enliven Therapeutics Director Richard A. Heyman Reports Disposal of Common Shares

Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares

Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares

Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares

Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data

Simply Wall St.

Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott

Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)

Enliven Therapeutics Up Over 58%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk

Enliven Therapeutics Shares Surge on Positive Initial Data for Leukemia Treatment

Enliven Therapeutics Reports Positive Phase 1b Results for ELVN-001 in CML

BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026

Enliven Therapeutics Inc - Continues to Prepare for Phase 3 Trial Initiation in 2026 and the Commercialization of Elvn-001

THOMSON REUTERS

Enliven Therapeutics Appoints Scott Garland to Board as Andrew Phillips Steps Down

Press Release: Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares

Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial

Simply Wall St.

Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair

Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ELVN/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELVN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","market":"US","secType":"STK","nameCN":"Enliven Treateutics","latestPrice":36.59,"timestamp":1774900800000,"preClose":38.83,"halted":0,"volume":2004290,"hourTrading":{"tag":"盘后","latestPrice":36.59,"preClose":36.59,"latestTime":"16:58 EDT","volume":14343,"amount":526154.53,"timestamp":1774904296632,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.057687355137779936,"floatShares":34999600,"shares":59800406,"eps":-1.83,"marketStatus":"Closed","change":-2.24,"latestTime":"03-30 16:00:00 EDT","open":38.29,"high":39.22,"low":35.6,"amount":74788044.99136,"amplitude":0.093227,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.83,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774944000000},"marketStatusCode":5,"adr":0,"listingDate":1583985600000,"exchange":"NASDAQ","adjPreClose":38.83,"preHourTrading":{"tag":"盘前","latestPrice":39.39,"preClose":38.83,"latestTime":"09:28 EDT","volume":374,"amount":14756.550358,"timestamp":1774877319072,"change":0.56,"changeRate":0.014422,"amplitude":0.058983},"postHourTrading":{"tag":"盘后","latestPrice":36.59,"preClose":36.59,"latestTime":"16:58 EDT","volume":14343,"amount":526154.53,"timestamp":1774904296632,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.752087,"impliedVol":0.7213,"impliedVolPercentile":0.7171},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELVN\",,,,,undefined,":{"symbol":"ELVN","floatShares":34999600,"roa":"-18.65%","roe":"-26.95%","lyrEps":-1.83,"volumeRatio":0.752087,"shares":59800406,"dividePrice":0,"high":39.22,"amplitude":0.093227,"preClose":38.83,"low":35.6,"week52Low":13.3,"pbRate":"4.76","week52High":40.62,"institutionHeld":0,"latestPrice":36.59,"eps":-1.83,"divideRate":0,"volume":2004290,"delay":0,"ttmEps":-1.83,"open":38.29,"prevYearClose":15.4,"prevWeekClose":38.83,"prevMonthClose":29.69,"prevQuarterClose":15.4,"fiveDayClose":30.81,"twentyDayClose":29.5,"sixtyDayClose":15.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELVN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-03","symbol":"ELVN","fiscalQuarterEnding":"2025/12","expectedEps":-0.42,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772514000000,"reportTimeType":"post","actualEps":-0.48},{"market":"US","date":"2025-11-12","symbol":"ELVN","fiscalQuarterEnding":"2025/09","expectedEps":-0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-13","symbol":"ELVN","fiscalQuarterEnding":"2025/06","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-14","symbol":"ELVN","fiscalQuarterEnding":"2025/03","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-0.57},{"market":"US","date":"2025-03-13","symbol":"ELVN","fiscalQuarterEnding":"2024/12","expectedEps":-0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.46}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELVN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELVN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.7,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7,"analysts":10,"updateTime":1755230400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELVN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELVN","date":"2026-03-27","current":-20.907104,"percent":0.042724,"low":-26.682642,"twenty":-16.515009,"median":-12.723654,"eighty":-10.654615,"high":-6.665619,"avg":-13.596602,"sd":3.957609,"marketCap":2349557951},"quantilePoints":[{"date":"2023-02-24","current":-26.682642,"twenty":-26.682642,"median":-26.682642,"eighty":-26.682642,"marketCap":974023148},{"date":"2023-03-03","current":-24.8289,"twenty":-26.345598,"median":-24.559265,"eighty":-24.199752,"marketCap":906354172},{"date":"2023-03-10","current":-23.694186,"twenty":-25.199648,"median":-24.28963,"eighty":-23.806534,"marketCap":864932556},{"date":"2023-03-17","current":-24.997422,"twenty":-25.053596,"median":-24.508708,"eighty":-23.817768,"marketCap":912505897},{"date":"2023-03-24","current":-25.045524,"twenty":-25.045524,"median":-24.501056,"eighty":-23.817768,"marketCap":943264523},{"date":"2023-03-31","current":-23.847695,"twenty":-25.154418,"median":-24.513309,"eighty":-23.847695,"marketCap":898151871},{"date":"2023-04-06","current":-25.11086,"twenty":-25.119572,"median":-24.513309,"eighty":-23.847695,"marketCap":945725213},{"date":"2023-04-14","current":-20.962015,"twenty":-25.076502,"median":-24.390743,"eighty":-23.811629,"marketCap":789471394},{"date":"2023-04-21","current":-21.332253,"twenty":-25.048753,"median":-24.119928,"eighty":-22.848051,"marketCap":803415304},{"date":"2023-04-28","current":-20.635334,"twenty":-25.016663,"median":-23.926845,"eighty":-21.458569,"marketCap":777167943},{"date":"2023-05-05","current":-20.341321,"twenty":-24.896309,"median":-23.847695,"eighty":-21.260383,"marketCap":766094838},{"date":"2023-05-12","current":-20.851059,"twenty":-24.795534,"median":-23.81078,"eighty":-20.994683,"marketCap":785292584},{"date":"2023-05-19","current":-21.89907,"twenty":-24.705543,"median":-23.593073,"eighty":-21.113722,"marketCap":824762787},{"date":"2023-05-26","current":-21.462399,"twenty":-24.613192,"median":-22.720646,"eighty":-21.211975,"marketCap":808316869},{"date":"2023-06-02","current":-18.734285,"twenty":-24.559265,"median":-21.980633,"eighty":-20.954392,"marketCap":819006716},{"date":"2023-06-09","current":-21.377022,"twenty":-24.515759,"median":-21.83357,"eighty":-20.954392,"marketCap":934539290},{"date":"2023-06-16","current":-18.254642,"twenty":-24.497376,"median":-21.673899,"eighty":-20.758384,"marketCap":798038170},{"date":"2023-06-23","current":-20.812737,"twenty":-24.451411,"median":-21.642525,"eighty":-20.734427,"marketCap":909870413},{"date":"2023-06-30","current":-18.32988,"twenty":-24.28963,"median":-21.616844,"eighty":-20.341321,"marketCap":801327354},{"date":"2023-07-07","current":-17.361189,"twenty":-24.217728,"median":-21.517191,"eighty":-20.09872,"marketCap":758979115},{"date":"2023-07-14","current":-17.135475,"twenty":-24.135893,"median":-21.462399,"eighty":-19.332427,"marketCap":749111564},{"date":"2023-07-21","current":-17.972499,"twenty":-24.119928,"median":-21.435107,"eighty":-18.517975,"marketCap":785703732},{"date":"2023-07-28","current":-16.984999,"twenty":-23.971833,"median":-21.377022,"eighty":-18.220785,"marketCap":742533197},{"date":"2023-08-04","current":-16.881547,"twenty":-23.922067,"median":-21.256028,"eighty":-17.820142,"marketCap":738010570},{"date":"2023-08-11","current":-16.491696,"twenty":-23.861932,"median":-21.016461,"eighty":-17.568094,"marketCap":720967464},{"date":"2023-08-18","current":-12.980214,"twenty":-23.847695,"median":-20.922018,"eighty":-17.248332,"marketCap":669117064},{"date":"2023-08-25","current":-13.578933,"twenty":-23.823753,"median":-20.812737,"eighty":-17.129832,"marketCap":699980398},{"date":"2023-09-01","current":-12.469308,"twenty":-23.815574,"median":-20.736061,"eighty":-17.000046,"marketCap":642780353},{"date":"2023-09-08","current":-12.908368,"twenty":-23.809931,"median":-20.564155,"eighty":-16.862737,"marketCap":665413464},{"date":"2023-09-15","current":-13.123907,"twenty":-23.739125,"median":-20.333094,"eighty":-16.776213,"marketCap":676524264},{"date":"2023-09-22","current":-10.154264,"twenty":-23.633518,"median":-19.996164,"eighty":-15.495828,"marketCap":523442131},{"date":"2023-09-29","current":-10.968521,"twenty":-23.474031,"median":-19.373808,"eighty":-13.527842,"marketCap":565416265},{"date":"2023-10-06","current":-11.511359,"twenty":-23.372472,"median":-19.044642,"eighty":-13.224491,"marketCap":593399020},{"date":"2023-10-13","current":-9.994605,"twenty":-22.593241,"median":-18.52738,"eighty":-13.107941,"marketCap":515211909},{"date":"2023-10-20","current":-10.130315,"twenty":-22.058041,"median":-18.391011,"eighty":-12.999373,"marketCap":522207598},{"date":"2023-10-27","current":-9.555545,"twenty":-22.040989,"median":-18.292261,"eighty":-12.964248,"marketCap":492578798},{"date":"2023-11-03","current":-9.731169,"twenty":-21.920278,"median":-17.972499,"eighty":-12.485274,"marketCap":501632043},{"date":"2023-11-10","current":-7.695346,"twenty":-21.89907,"median":-17.817321,"eighty":-12.245786,"marketCap":475295332},{"date":"2023-11-17","current":-6.952736,"twenty":-21.83357,"median":-17.803213,"eighty":-11.215991,"marketCap":429428758},{"date":"2023-11-24","current":-7.786797,"twenty":-21.720035,"median":-17.492856,"eighty":-10.958941,"marketCap":480943724},{"date":"2023-12-01","current":-7.513225,"twenty":-21.68071,"median":-17.309463,"eighty":-10.760965,"marketCap":464046815},{"date":"2023-12-08","current":-7.506552,"twenty":-21.671453,"median":-17.210713,"eighty":-10.505512,"marketCap":463634696},{"date":"2023-12-15","current":-7.893557,"twenty":-21.652352,"median":-17.121368,"eighty":-10.333081,"marketCap":487537640},{"date":"2023-12-22","current":-8.620858,"twenty":-21.63925,"median":-17.013213,"eighty":-10.031327,"marketCap":532458691},{"date":"2023-12-29","current":-9.721819,"twenty":-21.630859,"median":-16.994403,"eighty":-9.985025,"marketCap":600458446},{"date":"2024-01-05","current":-9.735164,"twenty":-21.621546,"median":-16.919166,"eighty":-9.908649,"marketCap":601282686},{"date":"2024-01-12","current":-7.653347,"twenty":-21.612141,"median":-16.825118,"eighty":-9.735164,"marketCap":472701330},{"date":"2024-01-19","current":-8.547461,"twenty":-21.544748,"median":-16.787499,"eighty":-9.657763,"marketCap":527925374},{"date":"2024-01-26","current":-10.90285,"twenty":-21.510766,"median":-16.702856,"eighty":-9.657763,"marketCap":673403638},{"date":"2024-02-02","current":-10.972911,"twenty":-21.471637,"median":-15.246862,"eighty":-9.711143,"marketCap":677730895},{"date":"2024-02-09","current":-10.282309,"twenty":-21.462504,"median":-13.618847,"eighty":-9.729299,"marketCap":635076503},{"date":"2024-02-16","current":-11.543409,"twenty":-21.454109,"median":-13.399317,"eighty":-9.734365,"marketCap":712967132},{"date":"2024-02-23","current":-10.609261,"twenty":-21.445153,"median":-13.291548,"eighty":-9.761506,"marketCap":655270370},{"date":"2024-03-01","current":-10.655968,"twenty":-21.434015,"median":-13.147855,"eighty":-9.803015,"marketCap":658155208},{"date":"2024-03-08","current":-10.275636,"twenty":-21.409359,"median":-13.10395,"eighty":-9.82474,"marketCap":634664384},{"date":"2024-03-15","current":-6.665619,"twenty":-21.384546,"median":-13.044078,"eighty":-9.733566,"marketCap":477151673},{"date":"2024-03-22","current":-10.431636,"twenty":-21.350161,"median":-12.972231,"eighty":-9.727429,"marketCap":746738233},{"date":"2024-03-28","current":-10.760874,"twenty":-21.310474,"median":-12.880428,"eighty":-9.732767,"marketCap":770306384},{"date":"2024-04-05","current":-12.135517,"twenty":-21.260383,"median":-12.485274,"eighty":-9.752725,"marketCap":868708833},{"date":"2024-04-12","current":-15.541291,"twenty":-21.211975,"median":-12.53879,"eighty":-9.795033,"marketCap":1112507764},{"date":"2024-04-19","current":-11.553574,"twenty":-21.113722,"median":-12.520461,"eighty":-9.82282,"marketCap":827051011},{"date":"2024-04-26","current":-10.971645,"twenty":-20.994683,"median":-12.453342,"eighty":-9.833917,"marketCap":785394226},{"date":"2024-05-03","current":-13.724364,"twenty":-20.956933,"median":-12.42141,"eighty":-9.861485,"marketCap":982444863},{"date":"2024-05-10","current":-15.627075,"twenty":-20.927476,"median":-12.477291,"eighty":-9.897956,"marketCap":1118648510},{"date":"2024-05-17","current":-14.069999,"twenty":-20.877259,"median":-12.55712,"eighty":-9.908649,"marketCap":1119943779},{"date":"2024-05-24","current":-13.579529,"twenty":-20.83573,"median":-12.880428,"eighty":-9.913987,"marketCap":1080903320},{"date":"2024-05-31","current":-13.31952,"twenty":-20.807747,"median":-12.919935,"eighty":-9.925997,"marketCap":1060207172},{"date":"2024-06-07","current":-11.936748,"twenty":-20.777985,"median":-12.852488,"eighty":-9.949337,"marketCap":950141299},{"date":"2024-06-14","current":-13.012238,"twenty":-20.738783,"median":-12.908368,"eighty":-9.978639,"marketCap":1035748089},{"date":"2024-06-21","current":-12.433128,"twenty":-20.734427,"median":-12.823141,"eighty":-9.991412,"marketCap":989652125},{"date":"2024-06-28","current":-13.857265,"twenty":-20.713737,"median":-12.852488,"eighty":-9.999395,"marketCap":1103010568},{"date":"2024-07-05","current":-12.734501,"twenty":-20.635334,"median":-12.852488,"eighty":-10.018554,"marketCap":1013640841},{"date":"2024-07-12","current":-14.217731,"twenty":-20.492975,"median":-12.947875,"eighty":-10.03452,"marketCap":1131702953},{"date":"2024-07-15","current":-14.619562,"twenty":-20.462644,"median":-12.964248,"eighty":-10.034701,"marketCap":1163687908},{"date":"2024-08-02","current":-14.595925,"twenty":-20.432313,"median":-12.972231,"eighty":-10.034882,"marketCap":1161806440},{"date":"2024-08-09","current":-12.834959,"twenty":-20.33803,"median":-12.964248,"eighty":-10.054109,"marketCap":1021637080},{"date":"2024-08-16","current":-13.556309,"twenty":-20.306761,"median":-12.945278,"eighty":-10.088634,"marketCap":1122828410},{"date":"2024-08-23","current":-13.060138,"twenty":-20.227193,"median":-12.964248,"eighty":-10.111156,"marketCap":1081732040},{"date":"2024-08-30","current":-12.672326,"twenty":-20.030349,"median":-12.961651,"eighty":-10.130701,"marketCap":1049610739},{"date":"2024-09-06","current":-12.495529,"twenty":-19.786892,"median":-12.919935,"eighty":-10.135876,"marketCap":1034967205},{"date":"2024-09-13","current":-12.73506,"twenty":-19.581572,"median":-12.931502,"eighty":-10.154517,"marketCap":1054806832},{"date":"2024-09-20","current":-13.157091,"twenty":-19.368165,"median":-12.8873,"eighty":-10.156457,"marketCap":1089762365},{"date":"2024-09-27","current":-13.755918,"twenty":-19.332427,"median":-12.959054,"eighty":-10.16247,"marketCap":1139361432},{"date":"2024-10-04","current":-14.548651,"twenty":-19.185713,"median":-12.995005,"eighty":-10.191351,"marketCap":1205021150},{"date":"2024-10-11","current":-15.381306,"twenty":-18.794475,"median":-13.012238,"eighty":-10.271051,"marketCap":1273987472},{"date":"2024-10-18","current":-15.980134,"twenty":-18.692904,"median":-13.06278,"eighty":-10.276971,"marketCap":1323586540},{"date":"2024-10-25","current":-16.527633,"twenty":-18.517975,"median":-13.077247,"eighty":-10.282309,"marketCap":1368934258},{"date":"2024-10-31","current":-16.191149,"twenty":-18.480356,"median":-13.117169,"eighty":-10.282309,"marketCap":1341064306},{"date":"2024-11-08","current":-16.539039,"twenty":-18.452142,"median":-13.127899,"eighty":-10.308998,"marketCap":1369879003},{"date":"2024-11-15","current":-14.288385,"twenty":-18.32988,"median":-13.147855,"eighty":-10.377785,"marketCap":1217570416},{"date":"2024-11-22","current":-14.569336,"twenty":-18.254642,"median":-13.191309,"eighty":-10.377785,"marketCap":1241511408},{"date":"2024-11-29","current":-13.978765,"twenty":-18.119213,"median":-13.257473,"eighty":-10.420866,"marketCap":1191186467},{"date":"2024-12-06","current":-13.330857,"twenty":-17.99507,"median":-13.275582,"eighty":-10.465191,"marketCap":1135975609},{"date":"2024-12-13","current":-13.187514,"twenty":-17.927356,"median":-13.313517,"eighty":-10.47358,"marketCap":1123760818},{"date":"2024-12-20","current":-13.112976,"twenty":-17.840832,"median":-13.307514,"eighty":-10.475365,"marketCap":1117409126},{"date":"2024-12-27","current":-13.021237,"twenty":-17.81638,"median":-13.27352,"eighty":-10.487821,"marketCap":1109591659},{"date":"2025-01-03","current":-13.703547,"twenty":-17.808856,"median":-13.27352,"eighty":-10.502895,"marketCap":1167734067},{"date":"2025-01-10","current":-13.84689,"twenty":-17.803213,"median":-13.275582,"eighty":-10.521478,"marketCap":1179948858},{"date":"2025-01-17","current":-12.60841,"twenty":-17.759951,"median":-13.27352,"eighty":-10.564579,"marketCap":1074413060},{"date":"2025-01-24","current":-12.637079,"twenty":-17.586904,"median":-13.268745,"eighty":-10.609261,"marketCap":1076856018},{"date":"2025-01-31","current":-12.195584,"twenty":-17.492856,"median":-13.225528,"eighty":-10.642623,"marketCap":1039234460},{"date":"2025-02-07","current":-12.883628,"twenty":-17.445832,"median":-13.157091,"eighty":-10.649204,"marketCap":1097865460},{"date":"2025-02-14","current":-12.327459,"twenty":-17.361189,"median":-13.147855,"eighty":-10.655968,"marketCap":1050472069},{"date":"2025-02-21","current":-12.310258,"twenty":-17.278427,"median":-13.123907,"eighty":-10.661306,"marketCap":1049006294},{"date":"2025-02-28","current":-11.553409,"twenty":-17.220118,"median":-13.115073,"eighty":-10.671914,"marketCap":984512194},{"date":"2025-03-07","current":-12.304524,"twenty":-17.210713,"median":-13.077247,"eighty":-10.692528,"marketCap":1048517702},{"date":"2025-03-14","current":-11.168896,"twenty":-17.203189,"median":-13.06278,"eighty":-10.70156,"marketCap":994299783},{"date":"2025-03-21","current":-11.515688,"twenty":-17.148642,"median":-13.044078,"eighty":-10.73075,"marketCap":1025172571},{"date":"2025-03-28","current":-11.840461,"twenty":-17.112904,"median":-13.012192,"eighty":-10.756253,"marketCap":1054085181},{"date":"2025-04-04","current":-11.025775,"twenty":-17.062118,"median":-12.992568,"eighty":-10.756253,"marketCap":981558632},{"date":"2025-04-11","current":-8.207404,"twenty":-17.020737,"median":-12.961651,"eighty":-10.671914,"marketCap":730655976},{"date":"2025-04-17","current":-8.845942,"twenty":-17.00757,"median":-12.919935,"eighty":-10.646572,"marketCap":787501109},{"date":"2025-04-25","current":-10.073474,"twenty":-16.992523,"median":-12.900829,"eighty":-10.506428,"marketCap":896780977},{"date":"2025-05-02","current":-10.926692,"twenty":-16.945499,"median":-12.87493,"eighty":-10.47358,"marketCap":972737836},{"date":"2025-05-09","current":-10.268015,"twenty":-16.896595,"median":-12.837758,"eighty":-10.456802,"marketCap":914099729},{"date":"2025-05-16","current":-9.22086,"twenty":-16.864245,"median":-12.824716,"eighty":-10.419165,"marketCap":874414177},{"date":"2025-05-23","current":-8.677544,"twenty":-16.841798,"median":-12.774982,"eighty":-10.35027,"marketCap":822891456},{"date":"2025-05-30","current":-9.179465,"twenty":-16.826999,"median":-12.740411,"eighty":-10.284647,"marketCap":870488636},{"date":"2025-06-06","current":-11.057788,"twenty":-16.804427,"median":-12.734501,"eighty":-10.282309,"marketCap":1048610043},{"date":"2025-06-13","current":-10.172958,"twenty":-16.787499,"median":-12.717951,"eighty":-10.278305,"marketCap":964701612},{"date":"2025-06-20","current":-13.417901,"twenty":-16.781856,"median":-12.734501,"eighty":-10.282309,"marketCap":1272419584},{"date":"2025-06-27","current":-13.386798,"twenty":-16.747999,"median":-12.73478,"eighty":-10.283478,"marketCap":1269470072},{"date":"2025-07-03","current":-12.895368,"twenty":-16.702856,"median":-12.73478,"eighty":-10.288155,"marketCap":1222867778},{"date":"2025-07-11","current":-14.170598,"twenty":-16.684047,"median":-12.73506,"eighty":-10.29197,"marketCap":1343797781},{"date":"2025-07-18","current":-14.518953,"twenty":-16.539039,"median":-12.769279,"eighty":-10.308998,"marketCap":1376832318},{"date":"2025-07-25","current":-13.654285,"twenty":-16.539039,"median":-12.823141,"eighty":-10.377785,"marketCap":1294835877},{"date":"2025-08-01","current":-11.701007,"twenty":-16.527633,"median":-12.814277,"eighty":-10.377785,"marketCap":1109606508},{"date":"2025-08-08","current":-11.13493,"twenty":-16.527633,"median":-12.763576,"eighty":-10.392743,"marketCap":1055925385},{"date":"2025-08-15","current":-11.683894,"twenty":-16.52193,"median":-12.73478,"eighty":-10.409257,"marketCap":1170901400},{"date":"2025-08-22","current":-11.727119,"twenty":-16.516227,"median":-12.729357,"eighty":-10.425771,"marketCap":1175233252},{"date":"2025-08-29","current":-12.034483,"twenty":-16.491696,"median":-12.666623,"eighty":-10.431636,"marketCap":1206035736},{"date":"2025-09-05","current":-11.827604,"twenty":-16.470258,"median":-12.655877,"eighty":-10.465191,"marketCap":1185303295},{"date":"2025-09-12","current":-11.774406,"twenty":-16.437524,"median":-12.642812,"eighty":-10.47358,"marketCap":1179972096},{"date":"2025-09-19","current":-11.777361,"twenty":-16.362242,"median":-12.617902,"eighty":-10.475365,"marketCap":1180268273},{"date":"2025-09-26","current":-10.976442,"twenty":-16.281259,"median":-12.614144,"eighty":-10.477125,"marketCap":1100004107},{"date":"2025-10-03","current":-11.774406,"twenty":-16.205977,"median":-12.604497,"eighty":-10.492153,"marketCap":1179972096},{"date":"2025-10-10","current":-12.584192,"twenty":-16.158355,"median":-12.584192,"eighty":-10.509962,"marketCap":1261124795},{"date":"2025-10-17","current":-12.856091,"twenty":-16.100826,"median":-12.570656,"eighty":-10.522555,"marketCap":1288373147},{"date":"2025-10-24","current":-12.146789,"twenty":-16.047431,"median":-12.55712,"eighty":-10.547691,"marketCap":1217290490},{"date":"2025-10-31","current":-14.168299,"twenty":-16.017711,"median":-12.59139,"eighty":-10.598091,"marketCap":1419876061},{"date":"2025-11-07","current":-10.816849,"twenty":-16.012848,"median":-12.55712,"eighty":-10.635951,"marketCap":1084010510},{"date":"2025-11-14","current":-12.003893,"twenty":-15.986677,"median":-12.54534,"eighty":-10.635951,"marketCap":1202970115},{"date":"2025-11-21","current":-12.98587,"twenty":-15.975572,"median":-12.55712,"eighty":-10.647888,"marketCap":1262317432},{"date":"2025-11-28","current":-13.187343,"twenty":-15.974431,"median":-12.598588,"eighty":-10.653262,"marketCap":1281902047},{"date":"2025-12-05","current":-13.065238,"twenty":-15.940212,"median":-12.601543,"eighty":-10.659972,"marketCap":1270032583},{"date":"2025-12-12","current":-11.459557,"twenty":-15.886602,"median":-12.584192,"eighty":-10.669596,"marketCap":1113949140},{"date":"2025-12-19","current":-10.183559,"twenty":-15.842118,"median":-12.556807,"eighty":-10.629278,"marketCap":989913247},{"date":"2025-12-26","current":-10.214086,"twenty":-15.803337,"median":-12.543135,"eighty":-10.536256,"marketCap":992880613},{"date":"2026-01-02","current":-9.402087,"twenty":-15.766837,"median":-12.530924,"eighty":-10.485339,"marketCap":913948681},{"date":"2026-01-09","current":-14.194709,"twenty":-15.757712,"median":-12.525083,"eighty":-10.474026,"marketCap":1379825120},{"date":"2026-01-16","current":-15.366918,"twenty":-15.766837,"median":-12.533872,"eighty":-10.476139,"marketCap":1493771968},{"date":"2026-01-23","current":-16.502494,"twenty":-15.873654,"median":-12.554602,"eighty":-10.477453,"marketCap":1604157978},{"date":"2026-01-30","current":-15.67218,"twenty":-15.873654,"median":-12.55712,"eighty":-10.482717,"marketCap":1523445627},{"date":"2026-02-06","current":-16.478073,"twenty":-15.974431,"median":-12.601543,"eighty":-10.495828,"marketCap":1601784085},{"date":"2026-02-13","current":-16.581863,"twenty":-16.012848,"median":-12.60841,"eighty":-10.513495,"marketCap":1611873129},{"date":"2026-02-20","current":-15.971338,"twenty":-16.047431,"median":-12.614144,"eighty":-10.522555,"marketCap":1552525812},{"date":"2026-02-27","current":-18.083755,"twenty":-16.148743,"median":-12.62937,"eighty":-10.547691,"marketCap":1757867529},{"date":"2026-03-06","current":-16.891565,"twenty":-16.308347,"median":-12.642812,"eighty":-10.598091,"marketCap":1751553891},{"date":"2026-03-13","current":-16.614748,"twenty":-16.467534,"median":-12.654701,"eighty":-10.635951,"marketCap":1722849696},{"date":"2026-03-20","current":-17.329857,"twenty":-16.467534,"median":-12.66092,"eighty":-10.647888,"marketCap":1797002200},{"date":"2026-03-27","current":-22.658572,"twenty":-16.515009,"median":-12.723654,"eighty":-10.654615,"marketCap":2349557951}],"updateTime":1774882221236},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELVN\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608847851","title":"Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2608847851","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608847851?lang=en_us&edition=fundamental","pubTime":"2026-02-03 14:17","pubTimestamp":1770099467,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) is back in focus after Chief Scientific Officer Joseph P. Lyssikatos sold 20,000 shares, following encouraging early ELVN-001 leukemia trial data and as the company prepares for potential later stage studies.\nSee our latest analysis for Enliven Therapeutics.\nAt a latest share price of $28.17, Enliven’s recent 1 month share price return of 81.27% and 90 day share price return of 48.19% suggest strong momentum. The 1 year total shareholder return of 28.63% points to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-cso-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-cso-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4139","LENZ","PRGS","BK4539","BK4007","BK4097","ELVN","DCF"],"gpt_icon":0},{"id":"2605443317","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443317","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443317?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:35","pubTimestamp":1769121315,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL3yjyfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2605381443","title":"Enliven Therapeutics Director Richard A. Heyman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605381443","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605381443?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:33","pubTimestamp":1769121225,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director, reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL7Ll0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Richard A. Heyman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2603655751","title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603655751","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603655751?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:54","pubTimestamp":1768344892,"startTime":"0","endTime":"0","summary":"Anish Patel, Chief Operating Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1ZPHb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics COO Anish Patel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2603025529","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603025529","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603025529?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:13","pubTimestamp":1768256011,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6Gtb2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2603290175","title":"Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603290175","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603290175?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:11","pubTimestamp":1768255912,"startTime":"0","endTime":"0","summary":"Richard A. Heyman, Director, reported a disposal of common shares of Enliven Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbR6rfc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Director Richard A. Heyman Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2602539564","title":"Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539564","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602539564?lang=en_us&edition=fundamental","pubTime":"2026-01-11 02:16","pubTimestamp":1768069000,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) shares moved after the company released encouraging initial Phase 1b ENABLE data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients who are relapsed, refractory, or intolerant to existing tyrosine kinase inhibitors.\nSee our latest analysis for Enliven Therapeutics.\nThe latest ENABLE readout arrived alongside a board refresh, with industry veteran Scott Garland joining as a director. The stock has been highly reactive. Enliven Therapeutics has seen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-encourag","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/assessing-enliven-therapeutics-elvn-valuation-after-encourag","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4539","ELVN","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2602302161","title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302161","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302161?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:04","pubTimestamp":1767999882,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Garland J. Scott as the beneficial owner in his role as Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL3CZl28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for Director Garland J. Scott","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2602439631","title":"Analysts Are Bullish on Top Healthcare Stocks: Rubicon Organics (ROMJF), Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602439631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602439631?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:50","pubTimestamp":1767887440,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rubicon Organics (ROMJF – Research Report) and Enliv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-rubicon-organics-romjf-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-rubicon-organics-romjf-enliven-therapeutics-elvn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","BK4137","BK4588","ELVN","LU0128526141.USD","BK4539","BK4585","XBI","LU0029874061.USD","BK4581","LABU","BK4139","ROMJF","BK4007"],"gpt_icon":0},{"id":"2601952733","title":"Enliven Therapeutics Up Over 58%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601952733","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601952733?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:48","pubTimestamp":1767887280,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics, Inc.  is currently at $24.52, up $9.05 or 58.5%. --Would be highest close since Dec. 6, 2024, when it closed at $25.42. --On pace for largest percent increase since Sept. 7, 2022, when it rose 71.79%. --Currently up two consecutive days; up 61.96% over this period. --Down 88.83% from its all-time closing high of $219.48 on June 11, 2020. --Up 1.53% from 52 weeks ago , when it closed at $24.15. --Up 64.45% from its 52-week closing low of $14.91 on April 10, 2025. --Traded as high as $25.59; highest intraday level since Dec. 9, 2024, when it hit $25.67. --Up 65.42% at today's intraday high; largest intraday percent increase since Sept. 7, 2022, when it rose as much as 74.36%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2601393978","title":"Enliven Therapeutics Shares Surge on Positive Initial Data for Leukemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2601393978","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601393978?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:03","pubTimestamp":1767884580,"startTime":"0","endTime":"0","summary":"Shares of Enliven Therapeutics were sharply higher after the biotechnology company reported positive initial data from a Phase 1b trial for a leukemia treatment.The stock was up 61% at $24.95 in Thursday morning trading. Shares have stayed roughly flat over the past year.Enliven said the treatment, ELVN-001, had a cumulative major molecular response rate of 69% by 24 weeks among patients with chronic myeloid leukemia that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors.Enliven Chief Medical Officer Helen Collins said the company is preparing to work with the Food and Drug Administration to initiate a Phase 3 trial in the second half of the year.\"We are excited about these initial Phase 1b data, the progress we made throughout 2025 and the year ahead,\" Collins said. \"Our data continue to demonstrate that ELVN-001 has the potential to be the best-in-class active-site TKI for the treatment of CML and an important treatment option across all lines of therapy.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4539","ELVN"],"gpt_icon":0},{"id":"2601792367","title":"Enliven Therapeutics Reports Positive Phase 1b Results for ELVN-001 in CML","url":"https://stock-news.laohu8.com/highlight/detail?id=2601792367","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601792367?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:01","pubTimestamp":1767880900,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. announced positive initial data from its ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia  who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors. As of December 22, 2025, 60 patients were enrolled across different dosing cohorts. The cumulative major molecular response  rate was 69% by 24 weeks, with 53% of patients achieving MMR within that period. ELVN-001 demonstrated a favorable safety and tolerability profile across all tested doses, with no new safety signals identified. Additional Phase 1 data are expected to be presented mid-2026, and the company plans to align with the FDA on dose selection and initiate a Phase 3 trial in the second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL17hNgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2601033801","title":"BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601033801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601033801?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797230,"startTime":"0","endTime":"0","summary":"BRIEF-Enliven Therapeutics Continues To Prepare For Phase 3 Trial Initiation In 2026 Jan 7 (Reuters) - Enliven Therapeutics Inc ELVN.O:ENLIVEN THERAPEUTICS INC - CONTINUES TO PREPARE FOR PHASE 3 TRIAL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y8167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2601098628","title":"Enliven Therapeutics Inc - Continues to Prepare for Phase 3 Trial Initiation in 2026 and the Commercialization of Elvn-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2601098628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601098628?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:06","pubTimestamp":1767794768,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y8167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2601806733","title":"Enliven Therapeutics Appoints Scott Garland to Board as Andrew Phillips Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806733","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806733?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:01","pubTimestamp":1767794518,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has appointed Scott Garland to its Board of Directors as the company prepares for late-stage development and potential commercialization of ELVN-001. Andrew Phillips, Ph.D., will step down from the Board, effective January 7, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL9qxPJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELVN"],"gpt_icon":0},{"id":"2601806702","title":"Press Release: Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806702?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:00","pubTimestamp":1767794400,"startTime":"0","endTime":"0","summary":"Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors. Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001. BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effective January 7, 2026, as the Company transitions its focus to late-stage development and commercialization.\"We are pleased to welcome Scott Garland to our Board at this next stage of Enliven's development. Scott brings vast experience spanning oncology and hematology commercialization at both big pharma and early commercial-stage bio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","LENZ","BK4007","BK4539","BK4139"],"gpt_icon":0},{"id":"2593449414","title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2593449414","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593449414?lang=en_us&edition=fundamental","pubTime":"2025-12-24 07:45","pubTimestamp":1766533558,"startTime":"0","endTime":"0","summary":"Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL8FTnrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2591125666","title":"Enliven Therapeutics (ELVN): Taking Stock of Valuation After Leadership Shift and Upcoming ELVN-001 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591125666","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591125666?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:18","pubTimestamp":1765779487,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics (ELVN) just reshuffled its top ranks, naming industry veteran Richard Fair as CEO, President, and board member, while co founder Sam Kintz shifts to Head of Pipeline to focus on R and D.\nSee our latest analysis for Enliven Therapeutics.\nThe leadership shake up lands after a rough stretch for the stock, with a 7 day share price return of minus 22.7 percent and a 1 year total shareholder return of minus 27.17 percent. This suggests momentum has been fading despite the late...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-elvn/enliven-therapeutics/news/enliven-therapeutics-elvn-taking-stock-of-valuation-after-le","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","BK4539","ELVN","LENZ"],"gpt_icon":0},{"id":"2591728682","title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","url":"https://stock-news.laohu8.com/highlight/detail?id=2591728682","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591728682?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:30","pubTimestamp":1765582248,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Richard A. Fair as the beneficial owner, serving as President, CEO, and Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL5cTZTs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Enliven Therapeutics Files Initial Beneficial Ownership Statement for President and CEO Richard A. Fair","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0},{"id":"2590557541","title":"Enliven Therapeutics Grants CEO Richard Fair Stock Option Inducement Package","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557541","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590557541?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:22","pubTimestamp":1765488151,"startTime":"0","endTime":"0","summary":"Enliven Therapeutics Inc. has granted an inducement stock option to Richard Fair, the company's new President and Chief Executive Officer. Fair received an option to purchase 875,000 shares of Enliven's common stock at an exercise price of $18.77 per share, which was the closing price on the grant date. The option will vest with 25% of the shares vesting on the first anniversary of the grant, and the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 11, 2025, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7SYxdz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}